Dowling & Yahnke LLC Prometheus Biosciences, Inc. Call Options Transaction History
Dowling & Yahnke LLC
- $215 Million
- Q3 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RXDX
# of Institutions
2Shares Held
29.6KCall Options Held
0Put Options Held
0About Prometheus Biosciences, Inc.
- Ticker RXDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,904,100
- Description
- Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...